Switzerland The President of FASMED—the Swiss medical technology industry and trade association—elaborates on the plans to join forces with Medical Cluster, the other national medical technology organization, and highlights the current challenges facing the industry in Switzerland. Mr Gasche, you have a very interesting background, in the sense that you have…
Switzerland The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also highlighting the gaps around early stage funding and the ability of different cantons to collaborate on economic development. Switzerland of course has quite the reputation as a hub for biotech activity – how…
Switzerland For the eighth year in a row the World Economic Forum has ranked Switzerland first in both global competitiveness and in innovation; economiesuisse CEO Monika Rühl discusses the main issues which threaten this leading position, and the overall growth prospects for the Swiss economy. To begin, could you please introduce…
Luxembourg Founded just five years ago, the Luxembourg Pharmaceutical Association (APL) was created in response to the divergence of Luxembourg’s pharmaceutical regulatory environment with Belgium. At present, Secretary General Hendrik Kühne’s primary objective is to build a stronger dialogue and greater trust with the authorities, such that the industry can be…
Switzerland Walter P. Hölzle, president of vips, discusses the current priorities of the association, the importance of innovation, and the challenges of the current pricing system. While growth is close to zero for many pharmaceutical markets in Europe, Swiss pharma spending increased 4.5 percent in 2015. What would you identify as…
Philippines Higinio “JP” Porte, president of the Philippine Pharmaceutical Manufacturers Association, discusses how his extensive pharmaceutical background led him to his current role as well as the main objectives of the association moving forward. He also discusses his work to create comradery within the association, fostering an environment where members are…
Mexico Mayra Galindo Leal, general director of the Mexican Association of the Fight Against Cancer (AMLCC) provides an overview of the main milestones of this association that stands as the most important patient organization for cancer in Mexico, her expectations towards the pharmaceutical industry, and the main challenges she faces when…
Luxembourg Luxembourg has a young and ambitious life sciences community, which has identified four aspects of personalized medicine where the country has significant potential: digital health, neurodegenerative diseases, molecular diagnostics and immune-oncology. Thomas Dentzer, Head of the Life Sciences sector in Luxembourg, discusses the flexible and supportive atmosphere for companies and…
Luxembourg Jean-Paul Schuler, CEO of Luxinnovation – Luxembourg’s National Agency for Innovation and Research –, explains how his team is working hard to contribute to Luxembourg’s economic development by fostering innovation, fueling international growth and attracting foreign direct investment. He also explains why Luxembourg is an excellent place for companies looking to…
Singapore CEO of the Asia Pacific Medical Technology Association (APACMed), Fredrik Nyberg explains the rationale behind the creation of the first regional medical technology association; the industry challenges ahead, and the critical importance of bringing together all industry stakeholders to effectively advance the development of medical technology across Asia Pacific. …
Mexico Alexis Serlin, country president of Novartis Mexico and president of CANIFARMA, the industry chamber that brings together multinational and local drug manufacturers, explains how the pharmaceutical industry in Mexico aims to be recognized as a strategic sector by both the Ministries of Health and Economy. He highlights Novartis Mexico’s leadership in…
Switzerland Thomas Cueni of Interpharma, the Association of Pharmaceutical Research Companies of Switzerland, on the trend of major international companies developing significant operations in Switzerland; how 70 percent of employees at the top pharma companies are foreigners; and why the pharmaceutical industry is the exception to the rule when it comes…
See our Cookie Privacy Policy Here
